Examination of the relationship between symptoms of prostatitis and histological inflammation: Baseline data from the REDUCE chemoprevention trial

被引:80
作者
Nickel, J. Curtis
Roehrborn, Claus G.
O'Leary, Michael P.
Bostwick, David G.
Somerville, Matthew C.
Rittmaster, Roger S.
机构
[1] Queens Univ, Kingston Gen Hosp, Dept Urol, Kingston, ON K7L 2V7, Canada
[2] Univ Texas, SW Med Ctr Dallas, Dept Urol, Dallas, TX 75235 USA
[3] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Surg,Div Urol, Boston, MA 02115 USA
[4] Bostwick Labs, Glen Allen, VI USA
[5] GlaxoSmithKline Inc, Res Triangle Pk, NC USA
关键词
prostate; biopsy; inflammation; urination disorders; prostatitis;
D O I
10.1016/j.juro.2007.05.041
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Symptoms of abacterial chronic prostatitis/chronic pelvic pain syndrome are considered to be associated with prostate inflammation. The ongoing Reduction by Dutasteride of Prostate Cancer Events trial is a 4-year, phase III, placebo controlled study to determine whether 0.5 mg dutasteride daily decreases the risk of biopsy detectable prostate cancer. All men underwent biopsy before study entry, allowing review of the relationship between histological prostate inflammation and prostatitis symptoms. Materials and Methods: Eligible men were 50 to 75 years old with serum prostate specific antigen 2.5 ng/ml or greater and 10 ng/ml or less (ages 50 to 60 years), or 3.0 ng/ml or greater and 10 ng/ml or less (older than 60 years), and an International Prostate Symptom Score of less than 25 (or less than 20 if already on a-blocker therapy). Acute prostatitis was an exclusion criterion. The National Institutes of Health Chronic Prostatitis Symptom Index was used to assess prostatitis-like symptoms. Spearman rank correlations were used to assess the relationship between acute and chronic inflammation, and Chronic Prostatitis Symptom Index scores for the pain, urinary symptoms and quality of life domains as well as average pain, total score and prostatitis-like symptoms. Results: Data were available on 5,597 patients. The distribution of inflammation status was similar for those with and without chronic prostatitis-like symptoms. Significant correlations were found between average chronic inflammation, and total Chronic Prostatitis Symptom Index score and subscores for urinary symptoms and quality of life but the magnitude of these correlations was small. Conclusions: A lack of clinically meaningful association was found between prostatitis-like pain symptoms and histological inflammation in the Reduction by Dutasteride of Prostate Cancer Events population, suggesting that the view that symptoms of chronic prostatitis/chronic pelvic pain syndrome and prostate inflammation are associated needs further scrutiny.
引用
收藏
页码:896 / 900
页数:5
相关论文
共 19 条
[1]   Chemoprevention of prostate cancer in men at high risk: Rationale and design of the reduction by dutasteride of prostate cancer events (reduce) trial [J].
Andriole, G ;
Bostwick, D ;
Brawley, O ;
Gomella, L ;
Tindall, D ;
Breed, S ;
Somerville, M ;
Rittmaster, R .
JOURNAL OF UROLOGY, 2004, 172 (04) :1314-1317
[2]   Relation between acute urinary retention, chronic prostatic inflammation and accompanying elevated prostate-specific antigen [J].
Kefi, A ;
Koseoglu, H ;
Celebi, I ;
Yorukoglu, K ;
Esen, A .
SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 2006, 40 (02) :155-160
[3]   PATTERNS OF INFLAMMATION IN PROSTATIC HYPERPLASIA - HISTOLOGIC AND BACTERIOLOGIC STUDY [J].
KOHNEN, PW ;
DRACH, GW .
JOURNAL OF UROLOGY, 1979, 121 (06) :755-760
[4]   NIH consensus definition and classification of prostatitis [J].
Krieger, JN ;
Nyberg, L ;
Nickel, JC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (03) :236-237
[5]   Effects of finasteride in patients with inflammatory chronic pelvic pain syndrome: A double-blind, placebo-controlled, pilot study [J].
Leskinen, M ;
Lukkarinen, O ;
Marttila, T .
UROLOGY, 1999, 53 (03) :502-505
[6]   The National Institutes of Health chronic prostatitis symptom index: Development and validation of a new outcome measure [J].
Litwin, MS ;
McNaughton-Collins, M ;
Fowler, FJ ;
Nickel, JC ;
Calhoun, EA ;
Pontari, MA ;
Alexander, RB ;
Farrar, JT ;
O'Leary, MP .
JOURNAL OF UROLOGY, 1999, 162 (02) :369-375
[7]  
Nickel J C, 1994, Can J Urol, V1, P1
[8]   The three As of chronic prostatitis therapy:: antibiotics, α-blockers and anti-inflammatories.: What is the evidence? [J].
Nickel, JC .
BJU INTERNATIONAL, 2004, 94 (09) :1230-1233
[9]   A randomized placebo-controlled multicentre study to evaluate the safety and efficacy of finasteride for male chronic pelvic pain syndrome (category IIIA chronic nonbacterial prostatitis) [J].
Nickel, JC ;
Downey, J ;
Pontari, MA ;
Shoskes, DA ;
Zeitlin, SI .
BJU INTERNATIONAL, 2004, 93 (07) :991-995
[10]   Leukocytes and bacteria in men with chronic prostatitis/chronic pelvic pain syndrome compared to asymptomatic controls [J].
Nickel, JC ;
Alexander, RB ;
Schaeffer, AJ ;
Landis, JR ;
Knauss, JS ;
Propert, KJ .
JOURNAL OF UROLOGY, 2003, 170 (03) :818-822